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Abstract 
The idiopathic inflammatory myopathies are a heterogeneous group of disorders affecting 
both adults and children. Clinical features can include muscle weakness, skin disease and 
internal organ involvement.  A large number of autoantibodies, directed against cytoplasmic 
or nuclear components, can now be identified in these patients and specific clinic-serological 
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syndromes have been described. Laboratory testing to identify many of these autoantibodies 
is becoming easier and here we discuss the clinical utility of autoantibodies in myositis both 
in terms of facilitating diagnosis, predicting disease course and informing management 
decisions. 
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Introduction 
Autoantibodies directed against intracellular antigens form part of the diagnosis in many 
rheumatological conditions. They can be detected in approximately 80% of adult and 60% of 
children with idiopathic inflammatory myopathies (IIM) and many are very disease specific; 
that is they are not found in healthy individuals or other rheumatological disorders. The 
prevalence of these ‘myositis specific autoantibodies’ (MSA) varies with age at disease onset 
and in some cases the population studied.(1) The specificity of many autoantibodies means 
they provide a useful means to confirm a suspected diagnosis of IIM, although it is 
noteworthy that their absence does not preclude this diagnosis. ‘Myositis associated 
autoantibodies’ (MAA) are typically identified in patients with overlap syndromes and these 
patients may or may not have muscle disease as a dominant feature. The term MSA can in 
some cases be considered a misnomer, as patients may have minimal or no muscle disease:  
Dermatomyositis sine myositis or amyopathic myositis is reported to account for 20-30% 
adult cases but is rare in juvenile disease. (2-5)  In addition, the most well described 
autoantibody derived myositis sub-group, the anti-synthetase syndrome, can be considered as 
a spectrum where patients with anti-Jo-1 autoantibodies commonly present with more diffuse 
disease with significant muscle involvement whilst those with anti-PL12, anti-KS and anti-OJ 
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are more likely to have disease restricted to the lung and may never develop muscle 
involvement. (6) The term MSA will continue to be used throughout this review for 
convenience.  
Here we discuss the utility of myositis specific and associated autoantibodies in disease 
diagnosis and adopting a stratified approach to further investigation and management. 
 
Diagnosis 
IIM is an umbrella term encompassing a heterogeneous group of conditions. The feature of 
dermatomyositis distinguishing it from other IIM subtypes is the characteristic rash however, 
similarly to the variability of muscle involvement, the pathognomic rash of DM can be subtle 
and easily missed and particularly in juvenile disease can be atypical. This can make the 
distinction between the classic sub-groups of dermatomyositis and polymyositis difficult. The 
rarity of IIM, combined with the potentially subtle examination findings and the general 
heterogenicity of these diseases can lead to diagnostic delay.  For inclusion body myositis 
(IBM) mean diagnostic delays of 4-5 years have been reported.(7,8)  
The use of appropriate classification criteria and the division of IIM into appropriate 
subgroups is important both clinically and for future research study design. Work to establish 
an international consensus for diagnostic criteria in IIM is ongoing.(9) The Bohan and Peter 
criteria although widely used have long been considered outdated and fail to consider the 
utility of autoantibody testing or other potentially useful diagnostic techniques such as MRI. 
Autoantibody testing can be an invaluable tool to assist with diagnosis in a patient with 
symptoms consistent with IIM, in addition to other patient groups such as those patients with 
‘idiopathic’ interstitial lung disease where an underlying connective tissue disease needs to be 
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excluded. The new classification criteria for adult and juvenile IIM currently in development 
includes anti-Jo-1 positivity as a variable in its model and in the absence of muscle biopsy 
this confers the highest score in predicting IIM.(9) We believe that other anti-synthetase and 
mysotis-specific autoantibodies should be considered to have a similar diagnostic ‘weight’ 
but unfortunately as yet testing for these autoantibodies is not always readily available.  
Anti-Jo-1 autoantibody testing is widely available and anti-Jo-1 is the most common 
autoantibody identified in adult patients with IIM but is rare in juvenile disease. A significant 
limitation of the clinical utility of autoantibodies in patients with myositis, particularly those 
with juvenile-onset disease, has been the availability of testing. Standard immunological 
techniques such as indirect immunofluorescence are of limited value and a negative 
antinuclear antibody (ANA) does not preclude the presence of autoantibodies in patients with 
myositis, many of which produce a cytoplasmic staining pattern. There is a growing interest 
in simple, non-specialised laboratory techniques to detect other autoantibodies in myositis 
and recent publications have reflected this with several recent papers describing techniques 
such as ELISA and laser bead immunoassays to detect different MSA, including those 
commonly found in juvenile disease.(10-14)  
 
Management 
Predicting disease course 
MSA are typically mutually exclusive and the identification of autoantibodies and subsequent 
serological patient sub-classification can provide more detailed prognostic information than 
the broader clinically defined entities such as, polymyositis and dermatomyositis. The disease 
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phenotype associated with many of the autoantibodies that can be identified in patients with 
IIM is now well established and has been the subject of recent reviews (15,16) (Figure 1)  
Myositis Syndromes 
Anti-synthetase syndrome 
The antisynthetase syndrome is well described and clinical features classically include 
myositis, interstitial lung disease, Raynaud’s phenommenon, mechanic’s hands, Gottron’s 
lesions, arthritis and pyrexia. Anti-Jo-1 is the most common MSA identifiable in adult 
patients with myositis and is found in approximately 30% of cases. The remaining 
antisynthetase autoantibodies (PL12, PL7, OJ, EJ, KS, Zo, Ha) can each be found in <5%. 
While all are associated with the antisynthetase syndrome features listed above, disease 
presentation and the prevalence of pulmonary manifestations, does vary depending on the 
specific associated autoantibody. While muscle disease is common in patients with anti-Jo1, 
anti-PL-7 or anti-EJ, patients with anti-PL-12, anti-KS or anti-OJ in contrast often have 
predominant ILD. (16) Of 166 Japanese patients with anti-synthetase antibodies; 29% anti-
Jo-1, 16% anti-EJ,10% anti-PL-7 and 11% anti-PL-12 presented initially with ILD alone, and 
although many subsequently developed myositis and other disease features, this was less 
likely in those with anti-PL-12, anti-KS and anti-OJ. In contrast, in those patients with 
myositis alone at presentation nearly all subsequently developed ILD during follow-up. (17) 
In this way the anti-synthetase syndrome can be thought of as a disease spectrum and those 
patients with early pulmonary involvement or predominant respiratory symptoms may 
initially present to the respiratory clinic. Anti-synthetase antibodies were retrospectively 
identified in 6.6% of 198 patients diagnosed of idiopathic interstitial pneumonia and crucially 
of those found to have an anti-synthetase antibody just under 50% had no extra-pulmonary 
features. (18) These patients are important to recognise as a diagnosis of CTD-associated 
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rather than idiopathic ILD is likely to influence both treatment and prognosis.  Isolated ILD 
without myositis in patients with anti-synthetase syndrome is a risk factor for poor 
survival.(19)  
The most common cause of death in this group is pulmonary fibrosis and patients with non-
Jo-1 antisynthetase antibodies have been found to have a worse survival than those with anti- 
Jo-1. (20) (6)  Non-Jo-1 patients have also been found to have a greater delay in diagnosis 
compared to Jo-1 patients. (20) This may reflect differences in disease presentation but also 
the reduced availability of testing for ‘non-standard’ autoantibodies.  As diagnostic delay 
may be a contributory factor to the prognostic difference seen, the potential clinical benefit of 
wider MSA testing is clearly evident.  
Anti-synthetase autoantibodies are rare in Juvenile-onset disease and are found in <5%. 
Where they have been identified patients appear to have a similar disease phenotype to adults 
and are at risk of developing ILD. This is an important complication and in a recent study of 
mortality in juvenile-onset IIM, while the number of deaths were small, ILD was the most 
common cause of death and anti-synthetase autoantibodies were associated with an increased 
risk of  mortality.(21)  
Clinically Amyopathic Myositis 
The term clinically amyopathic myositis (CADM) or myositis sine myositis is used to 
describe those patients who present with dermatological features of DM without any muscle 
involvement clinically or histologically. The prognosis in patients presenting in this way can 
vary widely but MSA identification can assist clinicians in monitoring for anticipated 
complications. For example, patients with anti-SAE have been described in UK, European 
and Japanese cohorts. (22-25) These patients typically present with CADM first, and then 
progress to myositis with a higher frequency of dysphagia and gastrointestinal disease.(25) In 
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contrast, patients with anti-MDA5 autoantibodies also commonly present with minimal or no 
muscle involvement, however, this autoantibody is associated with ILD in predominantly 
Caucasian cohorts and rapidly-progressive ILD with a high mortality in East Asian cohorts. 
(26) (27) (28) 
Amyopathic myositis is recognised in children but it is rare, and more often patients have 
mild or progressive muscle disease.(29,30). Anti-MDA5 and anti-SAE autoantibodies have 
both been described in juvenile-onset disease. Anti-SAE is rare and while the clinical 
phenotype has yet to be defined, disease presentation appears similar to that described in 
adults (personal data). Anti-MDA5 in contrast is relatively common in juvenile-onset disease 
and has been found in 38% of Japanese cohorts and 7.4% of UK Juvenile patients.(31,32) 
This is an important MSA to identify as similarly to adults there appears to be an association 
with ILD in UK children and rapidly-progressive ILD in Japanese children.(31,32) 
Necrotising Autoimmune Myositis 
Necrotising autoimmune myopathy is a recently recognised subgroup of IIM characterised by 
marked myofibre necrosis with minimal or no inflammatory infiltrate on muscle biopsy.  
Patients typically present with acute proximal weakness and a very high creatinine kinase 
level. (33) This pattern can also be seen as a result of drug or toxin exposure. Occasionally 
patients may present atypically with an insidious onset and may be misdiagnosed as muscular 
dystrophy. The detection of anti-SRP or anti-HMGCR autoantibodies both facilitates 
diagnosis and identifies those patients likely to respond to immunomodulatory drugs. Patients 
with anti-SRP autoantibodies may present with features such as dysphagia, cardiac muscle 
involvement and arthritis in addition to muscle disease. Furthermore, this group of patients 
may be refractory to standard myositis treatment regimens and require a more aggressive 
treatment approach.  Anti-HMGCR autoantibodies are strongly associated with necrotising 
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autoimmune myopathy and also statin use, although it is noteworthy that only 40-60% 
patients have previously been exposed to statins.(12,34)  
Inclusion body myositis 
Although classified as an IIM, inclusion body myositis has several features distinguishing it 
from other inflammatory myopathies including a characteristic pattern of weakness with 
slowly progressive muscle weakness and atrophy.  It is the most common acquired muscle 
disease in those over 50 years and unlike other IIM and connective tissue diseases in general, 
is more common in men.  Muscle biopsy typically reveals both inflammatory and 
degenerative features with characteristic findings including rimmed vacuoles and amyloid 
deposits that are absent in other IIM subtypes.  While both disease presentation and muscle 
histology are classically distinctive, diagnosis is difficult as the disease is rare, presentation 
can be atypical and the sensitivity of muscle biopsy at presentation can be poor, as many of 
the pathological features do not develop until later. (35,36) 
The relatively recent discovery of an autoantibody associated with IBM, anti-Mupp44, which 
targets cytosolic 5’-Nucleotidase 1A is an exciting finding. (37-40) Further studies have 
shown that this autoantibody has a high sensitivity and specificity for IBM, suggesting it 
would be a useful tool in identifying this patient group.(39-41) Anti-Mupp44 autoantibodies 
provide an important opportunity to identify patients with IBM at an earlier stage, preventing 
unnecessary treatment with immunosuppression, to which they would not be expected to 
respond, in addition to repeated invasive tests such as muscle biopsy in order to reach the 
diagnosis. 
Overlap Syndromes 
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Muscle inflammation can also occur in other connective tissue diseases, including 
Scleroderma, SLE and Sjogrens syndrome in addition to Rheumatoid Arthritis, so-called 
myositis overlap syndromes. These are not common and a recent analysis of overlap 
syndromes in a Brazilian myositis cohort identified overlap syndromes in 14% of 
patients.(42) In this context the identification of MAA or MSA is useful and can alert the 
clinician to an increased risk of muscle involvement in addition to other disease features in 
patients presenting with features of connective tissue disease. For example, in Scleroderma, 
patients with anti-PmScl autoantibodies often have a phenotype similar to the anti-synthetase 
syndrome. They are more likely to have limited cutaneous disease, muscle disease, ILD and 
calcinosis compared to anti-PmScl negative patients. They are less likely to develop 
pulmonary arterial hypertension and have a better overall survival. (43) 
While MAA including anti-PmScl, anti-U1-RNP and anti-Ku are typically associated with 
myositis-overlap, so-called MSA have also been identified in this patient group further 
blurring the boundaries between these two terms and reflecting challenges in disease 
classification. Furthermore, whilst MSA are typically mutually exclusive, other MAA such as 
anti-Ro52 can co-exist and may modify the disease phenotype. Anti-Ro52 has been identified 
in up to 56% of those with anti-Jo-1 autoantibodies, (44-46) and in some studies has been 
associated with more severe ILD. (47,48) A more recent study failed to confirm this but did 
show patients with anti-Ro52 autoantibodies in addition to anti-Jo-1 had more severe 
myositis, joint impairment, an increased incidence of malignancy and reduced survival. (49) 
It is important to note that the identification of a MAA such as anti-Ro52 does not preclude 
the presence of an MSA, the latter being more informative with regard to disease phenotype. 
Important disease complications 
Malignancy 
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Malignancy represents a major cause of mortality in adult patients with myositis and there is 
a clearly established association between DM and the development of malignancy. The 
increased risk is higher in patients with DM than PM, and overall there is a threefold increase 
in risk of malignant disease for all cancer subtypes after diagnosis of DM.(50,51) Standard 
clinical practice after making a diagnosis of IIM in an adult patient would be to conduct a 
‘malignancy screen’ although there is little guidance as to how extensive screening should be. 
MSA can be useful in identifying those patients who may be more likely to develop a 
malignancy and in whom screening should therefore be more thorough. Whilst no specific 
cancer sub-type is associated with DM, Anti-TIF1γ and anti-NXP2 autoantibodies have both 
been associated with an increased risk of malignancy in adult patients. (52) (53)It is 
intriguing that these autoantibodies are the most commonly identified in juvenile populations 
where no association with malignancy exists. (54,55) 
Interstitial lung disease 
ILD is a leading cause of mortality in both adult and juvenile-onset disease. As described 
above it is associated with the anti-synthetase syndrome, anti-MDA5 autoantibodies, overlap 
disease and may present in isolation with no or minimal muscle involvement. In East Asian 
populations rapidly progressive ILD in association with clinically amyopathic DM and anti-
MDA5 autoantibodies has been well described.(56,57) In this sub-population anti-MDA5 
autoantibodies are associated with a high mortality in both adults and children.(4,58,59) 
Interestingly a falling titre of anti-MDA5 been shown to reflect treatment response, 
suggesting a potential future use of some MSA in disease monitoring.(60-62)  
Screening for ILD with should be performed in all patients with myositis, with a minimum of 
a chest-x-ray and pulmonary function testing.  It should be remembered that x-ray is an 
insensitive tool in excluding ILD, and approximately, 10% of patients with ILD detected on 
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HRCT will have a normal chest x-ray, particularly early in the disease course. (63) Clinicians 
should therefore have a low threshold for repeat testing and HRCT particularly in those 
patients with an autoantibody profile that suggests they are at increased risk.  
Skin disease 
Skin disease in DM can be a major cause of morbidity, this is particularly so in juvenile-onset 
disease where skin ulceration and calcinosis are more common. Although rare in adults with 
IIM, calcinosis is a major cause of morbidity in patients with juvenile onset disease and 
occurs in up to 30% of cases. It typically affects pressure areas such as the elbows, knees, 
buttocks and digits and may lead to skin ulceration, pain from nerve entrapment and joint 
contractures. (50,64,65) In patients with juvenile-onset disease the presence of anti-NXP2 
autoantibodies substantially increases the risk of calcinosis.(55) Skin disease is also 
associated with the other major autoantibodies identified in juvenile-onset disease; anti-TIF1γ 
which is associated with skin ulceration, lipoatrophy and contractures (54,66) and anti-
MDA5 which is associated with both skin and oral ulceration.(31) In adult patients anti-
MDA5 positivity is associated with a distinct mucocutaneous phenotype characterised by 
skin ulceration, palmar papules, and oral pain/ulceration.(26)  In the future these patients may 
be managed differently, although at present there is a lack of evidence to recommend a 
differential treatment approach. 
 
Treatment approach 
The Cochrane review of evidence based treatment for IIM was updated in 2012 and again 
highlighted the lack of quality trials assessing treatment efficacy and toxicity in inflammatory 
myositis.(67) The heterogenicity of inflammatory myositis represents a significant barrier to 
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the development of a general standardised treatment approach and autoantibody profile 
represents a potential method to sub-divide patients into more homogenous groups who may 
benefit from differing treatment approaches. There is already evidence of a differential 
response to B-call depletion depending on autoantibody status in subanalysis of the 
Rituximab in Myositis study which predicted a shorter time to improvement in the presence 
of an antisynthetase, anti-Mi-2 or other autoantibody compared to the absence of 
autoantibodies. (68)A small retrospective review also suggested a differential response in 
terms of relapse rate and need for further Rituximab cycles.(69)  
 
Conclusions 
The clinical utility of a test can be considered as a measure of the health care value provided 
by the test. Autoantibody testing in inflammatory myositis will form part of new, up-to-date 
diagnostic criteria. They have the potential to sub-divide patients in such a way as to 
highlight those at risk of significant complications and thereby guide appropriate further 
screening and monitoring. While the evidence base for treatment in myositis is as yet limited 
it is likely that in the future autoantibody profile may also influence treatment choice. 
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Table 1. Clinicoserological syndromes in myositis.  Subdividing patients by autoantibody status enables prediction of the expected disease 
phenotype. 
 Anti-
synthetasea 
Most common 
Ab in adult-
onset disease 
Anti-MDA5 
Common in 
East Asian 
populations. 
 
Anti-SAE 
Rare. 5% 
adults with 
IIM  and <1% 
juvenile 
Anti-Mi2 
‘Classic DM’, 
associated 
with ~10% 
cases 
Anti-TIF1γ 
Most common 
Ab in juvenile-
onset disease 
Anti-NXP2 
Common in 
juvenile-onset 
Anti-SRP 
Rare. 5% 
adults 
Anti-
HMGCR 
Rare.6% 
adults. 
Associated 
with statin-use 
Muscle 
disease 
Typically 
present but 
variable 
dependant on 
Ab specificity 
Typically 
absent or 
minimal 
Initially 
amyopathic 
but progresses 
to muscle 
involvement 
Present Present Present Necrotising 
myopathy 
Necrotising 
myopathy 
Skin 
disease 
Gottrons. 
Mechanic’s 
hands 
DM rash plus 
mucocutaneou
s  ulceration 
and painful 
palmar 
papules 
DM rash DM rash DM rash. 
Ulceration and  
lipoatrophy 
described in 
juvenile-onset 
disease 
DM rash. 
Increased risk 
of calcinosis 
  
Joint 
disease 
Non-erosive 
inflammatory 
polyarthritis 
Inflammatory 
arthritis 
present 
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Lung 
disease 
ILD may be 
presenting 
feature 
ILD. RP-ILD 
in some 
populations 
      
Other 
organ 
systems 
Raynaud’s 
phenomenon. 
Pyrexia 
 Dysphagia    Cardiac 
involvement 
 
Maligna
ncy 
    Strongly 
associated in 
adult-onset 
disease 
Associated in 
adult-onset 
disease 
  
a (Jo-1, PL12, PL7, OJ, EJ, KS, Zo, Ha). Ab; Autoantibody. DM; dermatomyositis. ILD; interstitial lung disease. RP-ILD; Rapidly progressive 
interstitial lung disease 
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